ATOS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
8.7M
-11.9%
9.9M
-13.7%
11.4M
+23.6%
9.3M
+2.3%
9.0M
R&D
4.9M
+2.5%
4.8M
-22.4%
6.2M
+14.6%
5.4M
-2.4%
5.5M
SG&A
3.8M
-25.4%
5.1M
-3.6%
5.3M
+36.0%
3.9M
+9.7%
3.5M
Operating Income
-8694000
+11.9%
-9870000
+13.7%
-11436000
-23.6%
-9251000
-2.3%
-9040000
EBITDA
-8690000
+11.9%
-9866000
+13.7%
-11432000
-23.6%
-9247000
-2.3%
-9036000
Net Income
-8491000
+11.5%
-9589000
+12.3%
-10937000
-25.8%
-8692000
-3.2%
-8423000
EPS (Basic)
$-0.95
+14.4%
$-1.11
+12.6%
$-1.27
-21.0%
$-1.05
-7.1%
$-0.98
EPS (Diluted)
$-0.95
+14.4%
$-1.11
+12.6%
$-1.27
-21.0%
$-1.05
-7.1%
$-0.98
Shares (Diluted)
8.9M
+3.3%
8.6M
+0.4%
8.6M
-0.3%
8.6M
-0.1%
8.6M
Atossa Therapeutics (ATOS) โ€” Financials